{"disease":{"id":"her2-overexpressing-gastric-carcinoma","name":"her2 overexpressing gastric carcinoma"},"drugs":{"marketed":[{"drug_id":"capecitabine","indication_name":"Treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xeloda","generic_name":"capecitabine","company_name":"Cheplapharm","drug_phase":"marketed","molecular_target":"Thymidylate synthase","drug_class":"Nucleoside Metabolic Inhibitor [EPC]","quality_score":67,"revenue":null,"mechanism":"Xeloda works by inhibiting the enzyme thymidylate synthase, which is necessary for DNA synthesis in cancer cells."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04714190","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":351,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false},{"nct_id":"NCT03556345","title":"A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":127,"lead_sponsor_name":"RemeGen Co., Ltd.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}